<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03314324</url>
  </required_header>
  <id_info>
    <org_study_id>2017-001606-14</org_study_id>
    <secondary_id>2017/2555</secondary_id>
    <nct_id>NCT03314324</nct_id>
  </id_info>
  <brief_title>A Study of Patient Preference Between ODM-201 and Enzalutamide in Men With Metastatic Castrate-resistant Prostate Cancer</brief_title>
  <acronym>ODENZA</acronym>
  <official_title>A Study of Patient Preference Between ODM-201 and Enzalutamide in Men With Metastatic Castrate-resistant Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gustave Roussy, Cancer Campus, Grand Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gustave Roussy, Cancer Campus, Grand Paris</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess patient preference between ODM-201 and enzalutamide by patient preference
      questionnaire
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 29, 2017</start_date>
  <completion_date type="Anticipated">January 2022</completion_date>
  <primary_completion_date type="Anticipated">January 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Prospective, randomized, open-label, multicenter, cross-over phase II trial</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Patient preference</measure>
    <time_frame>up to 24 months</time_frame>
    <description>Patient preference (assessed by a single question) between ODM-201 and enzalutamide after completion of the second period of treatment.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Metastatic Castrate-resistant Prostate (CRPC) Cancer</condition>
  <arm_group>
    <arm_group_label>ODM-201</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Enzalutamide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ODM-201</intervention_name>
    <description>ODM-201: 600 mg (2 x 300 mg tablets) twice daily with food equivalent to a total daily dose of 1200 mg. ODM-201 should be taken at similar times day, approximately 12 hours between doses.</description>
    <arm_group_label>ODM-201</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Enzalutamide</intervention_name>
    <description>Enzalutamide: 160 mg/day (4 x 40 mg tablets) taken once a day preferably with food, preferably in the evening (Enzalutamide can generally be given with or without food, but in the present trial, it is preferable that it is given with food, to be consistent with ODM-201 intake).</description>
    <arm_group_label>Enzalutamide</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male patients older than 18 years

          -  Histologically confirmed adenocarcinoma of the prostate

          -  Evidence of metastatic disease (imaging can include bon scan, CT scan, PET choline,
             PET PSMA and MRI)

          -  Continued androgen deprivation therapy (ADT) either with LHRH agonists/antagonists or
             bilateral orchiectomy

          -  Serum testosterone &lt;0.50 ng/ml (1.7 nmol/L)

          -  Progressive disease (PSA progression or radiological progression or clinical
             progression) as per PCWG3 criteria

          -  ECOG 0-1 (2 is accepted if the impairement is not due to prostate cancer)

          -  Asymptomatic or mildly symptomatic (Brief Pain Inventory&lt;4) prostate cancer

          -  Information imparted to the patient and the informed consent form signed by the
             patient or his legal representative

          -  Ability to comply with the protocol procedures

          -  Patient affiliated to a social security system or beneficiary of the same

          -  Sexually active male subjects unless surgically sterile, must agree to use condoms as
             an effective barrier method and refrain from sperm donation, and/or their female
             partners of reproductive potential to use a method of effective birth control, during
             the study treatment and for 3 months after the end of the treatment

          -  adequate organ or bone marrow function as evidenced by:

          -  Hemoglobin ≥ 9 g/dL

          -  Absolute neutrophil count ≥ 1.5 x 109/L,

          -  Platelet count ≥ 100 x 109/L, (subject must not have received any growth factor within
             4 weeks or blood transfusion within 7 days of the hematology laboratory sample
             obtained at screening)

          -  AST/SGOT and/or ALT/SGPT ≤1.5 x ULN;

          -  Total bilirubin ≤ 1.5 x ULN, (except subjects with a diagnosis of Gilbert's disease),

          -  Serum creatinine ≤ 2 x ULN. If creatinine 1.0 - 1.5 x ULN, creatinine clearance will
             be calculated according to the CKDEPI formula and patients with creatinine clearance
             &lt;60 mL/min should be excluded.

        Exclusion Criteria:

          -  Prior treatment with abiraterone, enzalutamide, ODM-201, ARN- 509 or any other
             next-generation AR axis-targeting drug

          -  Prior treatment with a taxane for CRPC (prior treatment with a taxane for
             castration-sensitive or castration-naïve prostate cancer is allowed)

          -  Prior treatment with radium-223

          -  Patients receiving an investigational drug within 4 weeks prior to enrolment (approved
             drugs with a long history of use such as aspirin, statins, heparins, or metformin,
             even used in an experimental setting are accepted)

          -  Treatment with radiotherapy (external beam radiation therapy [EBRT], brachytherapy, or
             radiopharmaceuticals) within 2 weeks before randomization

          -  Known hypersensitivity to any of the study drugs, study drug classes, or excipients in
             the formulation of the study drugs

          -  Acute toxicities of prior treatments and procedures not resolved to grade &lt;=1 or
             baseline before randomisation.

          -  Had any of the following within 6 months before randomization: stroke, myocardial
             infarction, severe/unstable angina pectoris, coronary/peripheral artery bypass graft,
             congestive heart failure (New York Heart Association (NYHA) Class III or IV)

          -  Uncontrolled hypertension as indicated by a resting systolic blood pressure (BP) ≥160
             mmHg or diastolic BP ≥100 mmHg despite optimal medical management

          -  Had a prior malignancy. Adequately treated basal cell or squamous cell carcinoma of
             skin or superficial bladder cancer that has not spread behind the connective tissue
             layer (i.e., pTis, pTa, and pT1) is allowed, as well as any other cancer for which
             treatment has been completed ≥5 years before randomization and from which the subject
             has been disease-free

          -  A gastrointestinal disorder or procedure which is expected to interfere significantly
             with absorption of study treatment

          -  An active viral hepatitis, active human immunodeficiency infection(HIV), or chronic
             liver disease with a need for treatment.

          -  Any other serious or unstable illness or infection, or medical, social, or
             psychological condition, that could jeopardize the safety of the subject and/or his
             compliance with study procedures, or may interfere with the subject's participation in
             the study or evaluation of the study results

          -  Inability to swallow oral medications
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Karim FIZAZI, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Gustave Roussy</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Karim FIZAZI, MD, PhD</last_name>
    <phone>0142114317</phone>
    <phone_ext>+33</phone_ext>
    <email>karim.fizazi@gustaveroussy.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Geraldine MARTINEAU, MD</last_name>
    <phone>0142115607</phone>
    <phone_ext>+33</phone_ext>
    <email>geraldine.martineau@gustaveroussy.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <state>Val De Marne</state>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karim FIZAZI, MD</last_name>
      <phone>0142114317</phone>
      <phone_ext>+33</phone_ext>
      <email>karim.fizazi@gustaveroussy.fr</email>
    </contact>
    <contact_backup>
      <last_name>Geraldine MARTINEAU, MD</last_name>
      <phone>0142115607</phone>
      <phone_ext>+33</phone_ext>
      <email>geraldine.martineau@gustaveroussy.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Karim FIZAZI, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 13, 2017</study_first_submitted>
  <study_first_submitted_qc>October 17, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 19, 2017</study_first_posted>
  <last_update_submitted>February 16, 2018</last_update_submitted>
  <last_update_submitted_qc>February 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 19, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

